×
About 403 results

ALLMedicine™ Myeloproliferative Disease Center

Research & Reviews  147 results

IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driv...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670266
Molecular Cancer; Cai B, Liu Y et. al.

Dec 16th, 2021 - Stem Cell leukemia/lymphoma syndrome (SCLL) presents as a myeloproliferative disease which can progress to acute myeloid leukemia and is associated with the coincident development of B-cell and T-cell lymphomas. SCLL is driven by the constitutive ...

A Case of Thrombotic Vasculopathy in the Setting of High-Dose Hydroxyurea Use.
https://www.ncbi.nlm.nih.gov/pubmed/34882096
Wounds : a Compendium of Clinical Research and Practice; Michalak J, Simman R et. al.

Dec 10th, 2021 - This case study describes the presentation of a 76-year-old male with a past medical history that included atrial fibrillation, essential hypertension, coronary artery disease status post cardiac stent placement, heart failure, hyperlipidemia, thy...

Chronic Thromboembolic Pulmonary Hypertension Mimicking Acute Pulmonary Embolism: A Cas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475734
The American Journal of Case Reports; Kaulins R, Vitola B et. al.

Sep 22nd, 2021 - BACKGROUND Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension which is often caused by recurrent emboli. The reported prevalence in Latvia is 15.7 cases per million inhabitants. Several risk factors pred...

Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myel...
https://doi.org/10.1016/j.jconrel.2021.08.035
Journal of Controlled Release : Official Journal of the C... Wang S, Liu X et. al.

Aug 25th, 2021 - Discovery of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the therapy of chronic myeloid leukemia (CML), a malignant myeloproliferative disease characterized by abnormal activation of BCR-ABL fusion oncoprotein with protein tyrosi...

see more →

Guidelines  1 results

Prophylaxis and management of venous thromboembolism in patients with myeloproliferativ...
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.

Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...

see more →

Clinicaltrials.gov  5 results

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
https://clinicaltrials.gov/ct2/show/NCT04146038

Aug 23rd, 2021 - PRIMARY OBJECTIVE: I. Determine the tolerability of the addition of standard dose salsalate to the standard treatment combination of venetoclax + hypomethylating agent (HMA) (decitabine or azacitidine [5-azacytidine]). SECONDARY OBJECTIVES: I. Det...

MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
https://clinicaltrials.gov/ct2/show/NCT04994158

Aug 6th, 2021 - Splanchnic or abdominal vein thrombosis (SVT) comprises thrombosis of hepatic, portal, superior mesenteric, splenic vein in isolation or combination. It has a prevalence of 1-2% in the general population based on autopsy reports. However, 40-50% o...

Effect of Pharmacogenetics on Imatinib Plasma Level and Response
https://clinicaltrials.gov/ct2/show/NCT03262974

Aug 3rd, 2021 - Introduction: Chronic myeloid leukaemia (CML) is a myeloproliferative disease with an incidence of one to two cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. The introduction of imatinib,...

Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL
https://clinicaltrials.gov/ct2/show/NCT04053933

Aug 13th, 2019 - Study type An observational study conducted in different hematological centers in Belgium. Study objectives Primary objective: To assess the impact of newly started treatments on the QOL of patients suffering from myelodysplastic syndromes. Second...

CEP-701 (Lestaurtinib) in Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT00668421

Nov 26th, 2014 - Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic anemia (low red blood c...

see more →

News  8 results

Breaking Down the Epidemiology of AML
https://www.onclive.com/view/breaking-down-the-epidemiology-of-aml

Apr 2nd, 2021 - Transcript: Richard F. Schlenk, MD: Acute myeloid leukemia [AML] is a hematological disease focused on myeloid cells. It’s characterized by different mutations, which occur in the hematopoietic stem cells but also the hematopoietic progenitor ...

Ritchie Reflects on Research Underway in Myeloproliferative Neoplasms
https://www.onclive.com/view/ritchie-reflects-on-research-underway-in-myeloproliferative-neoplasms

Dec 20th, 2020 - Ellen K. Ritchie, MD Investigators are in the midst of exploring novel therapeutic regimens for patients with myeloproliferative neoplasms (MPNs), as well as working to obtain a deeper understanding of the biology of these rare conditions. With ...

Symptom Management, Risk Stratification Crucial in MPN Treatment
https://www.onclive.com/view/symptom-management-risk-stratification-crucial-in-mpn-treatment

Dec 20th, 2020 - James M. Rossetti, DO When it comes to the treatment of patients with myeloproliferative neoplasms (MPNs), assessing for potential disease-related symptoms is key, said James M. Rossetti, DO. Moreover, risk stratification in all of the diseases a...

Putting the Genome to Work in Breast Cancer
https://www.onclive.com/view/putting-the-genome-to-work-in-breast-cancer

Dec 5th, 2020 - Elaine R. Mardis, PhD, discusses genomic insights into resistance mechanisms in endocrine therapy. Although breast cancer is among the best-characterized tumor types, continuing efforts to refine the sequencing of the human genome are opening th...

Switch may increase supply of HSCs from cord blood
https://www.mdedge.com/hematology-oncology/article/187211/transplantation/switch-may-increase-supply-hscs-cord-blood
HT Staff

Jul 15th, 2016 - Cord blood donation Photo courtesy of NHS Researchers have discovered a genetic switch that could increase the supply of hematopoietic stem cells (HSCs) derived from cord blood, according to a paper published in Cell Stem Cell. However, experiment.

see more →